Consolidated Financial Highlights

*We adopt International Financial Reporting Standards

*Financial data for past 10 years

■1Q　■2Q(total)　■3Q(total)　■Full Year　●Full Year(%)

Revenue

(millions of yen)

Operating Income & Operating Income Ratio

(millions of yen)(%)

Profit Before Tax & Profit Before Tax Ratio

(millions of yen)(%)

Profit Attributable to Owners of
the Parent & Profit Attributable
to Owners of the Parent Ratio

(millions of yen)(%)

Basic Earnings per Share Attributable to Owners of the Parent

(yen)

Cash Dividends per Share & Dividend Payout Ratio

(yen)(%)

Research and Development Expenditures

(millions of yen)(%)

Cash Flow

■Cash Flow From Operating Activities 　■Free Cash Flow

(millions of yen)

The Precision Medicine Business is classified as a discontinued operation from the nine months ended December 31, 2024. As a result, revenue, business contribution profit, operating profit, and profit before tax represent the amount of continuing operations excluding the discontinued operation. Profit for the period and profit attributable to owners of the Company represent the sum of continuing operations and the discontinued operation. In addition, the results for the fiscal year ended March 2024 include discontinued operations.

*1.: Operating Profit Ratio = Operating Profit ÷ Revenue ×100 (%)
*2.: Profit Before Tax Rate = Profit Before Tax ÷ Revenue ×100 (%)
*3.: Profit Attributable to Owners of the Parent Ratio =Profit Attributable to Owners of the Parent ÷ Revenue ×100 (%)
*4.: Dividend Payout Ratio = Total Dividend ÷ Net Income ×100 (%)